Genocea Biosciences (NASDAQ:GNCA) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research note issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Stock Performance

Genocea Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.00. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The firm has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.